KMT2D mutation
|
SCCHN
|
KMT2D mutation
|
SCCHN
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
durvalumab + CP-675206 Sensitive: B - Late Trials
|
KMT2D mutation
|
Follicular Lymphoma
|
KMT2D mutation
|
Follicular Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
|
R-CHOP Resistant: C3 – Early Trials
|
KMT2D mutation
|
Diffuse Large B Cell Lymphoma
|
KMT2D mutation
|
Diffuse Large B Cell Lymphoma
|
chidamide Resistant: C3 – Early Trials
|
chidamide Resistant: C3 – Early Trials
|
KMT2D mutation
|
Diffuse Large B Cell Lymphoma
|
KMT2D mutation
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
KMT2D mutation
|
Marginal Zone Lymphoma
|
KMT2D mutation
|
Marginal Zone Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
KMT2D mutation
|
CRC
|
KMT2D mutation
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2D mutation
|
NSCLC
|
KMT2D mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2D mutation
|
CRC
|
KMT2D mutation
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KMT2D mutation
|
Cervical Cancer
|
KMT2D mutation
|
Cervical Cancer
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
anlotinib + sintilimab Sensitive: C3 – Early Trials
|
KMT2D mutation
|
Triple Negative Breast Cancer
|
KMT2D mutation
|
Triple Negative Breast Cancer
|
cyclophosphamide + epirubicin Resistant: C3 – Early Trials
|
cyclophosphamide + epirubicin Resistant: C3 – Early Trials
|
KMT2D mutation
|
CLL
|
KMT2D mutation
|
CLL
|
decitabine Sensitive: D – Preclinical
|
decitabine Sensitive: D – Preclinical
|
KMT2D mutation
|
CLL
|
KMT2D mutation
|
CLL
|
chidamide Sensitive: D – Preclinical
|
chidamide Sensitive: D – Preclinical
|
KMT2D mutation
|
CLL
|
KMT2D mutation
|
CLL
|
ibrutinib + chidamide Sensitive: D – Preclinical
|
ibrutinib + chidamide Sensitive: D – Preclinical
|
KMT2D mutation
|
CLL
|
KMT2D mutation
|
CLL
|
ibrutinib + decitabine Sensitive: D – Preclinical
|
ibrutinib + decitabine Sensitive: D – Preclinical
|